

Global Small Volume Parenteral Market Size study, by Packaging Type (Ampoules, Vials), Dose Type (Single-dose, Multiple-dose), Indication Type (Cancer Care, Diabetes), Form, and Regional Forecasts 2022–2032

<https://marketpublishers.com/r/G9AAB2A0D16AEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G9AAB2A0D16AEN

Abstracts

The Global Small Volume Parenteral (SVP) Market is valued at approximately USD 180.6 billion in 2023 and is poised to surge at a promising CAGR of more than 7.50% over the forecast period 2024–2032. As the pharmaceutical sector accelerates toward patient-centric innovation and precision drug delivery, the demand for SVPs—defined by injectable preparations typically under 100 mL—has gained compelling momentum. With rising chronic disease prevalence, particularly cancer and diabetes, SVPs are increasingly being utilized due to their rapid onset of action, bioavailability, and controlled dosage administration. These formulations are predominantly packed in vials and ampoules and serve as a critical interface between complex biologics and patient adherence, particularly in oncology and acute care settings. As biologic drugs and biosimilars reshape therapeutic landscapes, small volume parenterals are expected to be an integral part of future drug delivery ecosystems.

The market's expansion is underpinned by a series of synergistic drivers—ranging from the global escalation in non-communicable diseases and enhanced diagnostic pathways to rising demand for sterile, preservative-free formulations suitable for outpatient and at-home use. The single-dose category, especially, is gaining traction due to its minimal risk of contamination and convenience in critical care. At the same time, advanced aseptic processing, smart packaging technologies, and automation in fill-finish operations are bolstering the scalability and compliance of SVP manufacturing lines. However, the market faces bottlenecks such as complex regulatory requirements, infrastructural disparities in emerging economies, and supply chain disruptions, particularly concerning glass vial shortages and cold chain logistics.

Biopharmaceutical leaders are leveraging innovation through co-formulation strategies, lyophilized SVPs, and compatibility with wearable injectors, marking a notable transition toward self-administration in chronic care. Furthermore, the integration of digital health tools, real-time dose tracking, and intelligent packaging is fostering enhanced pharmacovigilance and treatment personalization. These advancements are driving competitive differentiation and fueling product pipeline diversification, especially as leading manufacturers align their portfolios with evolving healthcare delivery models, including hospital-to-home transitions and ambulatory infusion centers. Regulatory authorities have also begun fast-tracking SVP approvals for high-demand therapeutic areas, further enhancing commercial uptake.

From a regional standpoint, North America remains the forerunner in the SVP market, attributed to its sophisticated healthcare infrastructure, dominance in biologics development, and early adoption of parenteral nutrition and oncology injectables. The U.S. continues to invest in high-throughput aseptic manufacturing and advanced drug-delivery formats, while also maintaining an active clinical trial landscape. Europe follows closely, driven by favorable reimbursement policies, growing elderly population, and government-supported biosimilar penetration. Meanwhile, the Asia Pacific region is projected to experience the fastest growth, buoyed by an expanding pharmaceutical contract manufacturing base, rising awareness of injectable therapies, and increasing prevalence of metabolic and oncological disorders in densely populated nations such as India and China.

Major market player included in this report are:

Pfizer Inc.

Baxter International Inc.

Teva Pharmaceutical Industries Ltd.

Fresenius Kabi AG

Novartis AG

Sanofi S.A.

GlaxoSmithKline plc

Eli Lilly and Company

Dr. Reddy's Laboratories Ltd.

Hikma Pharmaceuticals PLC

B. Braun Melsungen AG

Otsuka Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

Anneal Pharmaceuticals, Inc.

AbbVie Inc.

The detailed segments and sub-segment of the market are explained below:

By Packaging Type

Ampoules

Vials

By Dose Type

Single-dose

Multiple-dose

By Indication Type

Cancer Care

Diabetes

By Form

Solution

Suspension

Emulsion

Lyophilized Powder

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL SMALL VOLUME PARENTERAL MARKET EXECUTIVE SUMMARY

- 1.1. Global Small Volume Parenteral Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Packaging Type
 - 1.3.2. By Dose Type
 - 1.3.3. By Indication Type
 - 1.3.4. By Form
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL SMALL VOLUME PARENTERAL MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Patient Preference & Convenience
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL SMALL VOLUME PARENTERAL MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Cancer and Diabetes
- 3.1.2. Shift Toward Biologics and Biosimilars
- 3.1.3. Growth of Outpatient and At-Home Care Models

3.2. Market Challenges

- 3.2.1. Regulatory Complexities in Sterile Manufacturing
- 3.2.2. Glass Vial Shortages and Supply-Chain Disruptions
- 3.2.3. High Capital Expenditure for Aseptic Fill-Finish Lines

3.3. Market Opportunities

- 3.3.1. Innovations in Smart Packaging and Wearable Injectors
- 3.3.2. Expansion of Lyophilized and Combination Formulations
- 3.3.3. Adoption of Single-Dose Formats to Enhance Safety

CHAPTER 4. GLOBAL SMALL VOLUME PARENTERAL MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL SMALL VOLUME PARENTERAL MARKET SIZE & FORECASTS BY PACKAGING TYPE 2022–2032

5.1. Segment Dashboard

5.2. SVP Market: Packaging Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. Ampoules

5.2.2. Vials

CHAPTER 6. GLOBAL SMALL VOLUME PARENTERAL MARKET SIZE & FORECASTS BY DOSE TYPE 2022–2032

6.1. Segment Dashboard

6.2. SVP Market: Dose Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Single-dose

6.2.2. Multiple-dose

CHAPTER 7. GLOBAL SMALL VOLUME PARENTERAL MARKET SIZE & FORECASTS BY REGION 2022–2032

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Packaging Type Breakdown Size & Forecasts, 2022–2032

7.1.1.2. Dose Type Breakdown Size & Forecasts, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

7.3.1. China Market

7.3.2. India Market

7.3.3. Japan Market

7.3.4. Australia Market

7.3.5. South Korea Market

7.3.6. Rest of Asia Pacific Market

7.4. Latin America Market

- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Pfizer Inc.
 - 8.1.2. Baxter International Inc.
 - 8.1.3. Teva Pharmaceutical Industries Ltd.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Pfizer Inc.
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Baxter International Inc.
 - 8.3.3. Teva Pharmaceutical Industries Ltd.
 - 8.3.4. Fresenius Kabi AG
 - 8.3.5. Novartis AG
 - 8.3.6. Sanofi S.A.
 - 8.3.7. GlaxoSmithKline plc
 - 8.3.8. Eli Lilly and Company
 - 8.3.9. Dr. Reddy's Laboratories Ltd.
 - 8.3.10. Hikma Pharmaceuticals PLC
 - 8.3.11. B. Braun Melsungen AG
 - 8.3.12. Otsuka Pharmaceutical Co., Ltd.
 - 8.3.13. Sun Pharmaceutical Industries Ltd.
 - 8.3.14. Amneal Pharmaceuticals, Inc.
 - 8.3.15. AbbVie Inc.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Small Volume Parenteral Market Size study, by Packaging Type (Ampoules, Vials), Dose Type (Single-dose, Multiple-dose), Indication Type (Cancer Care, Diabetes), Form, and Regional Forecasts 2022–2032

Product link: <https://marketpublishers.com/r/G9AAB2A0D16AEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9AAB2A0D16AEN.html>